Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.35 USD 0.99 ( 10.58%)
Last update at 2026-11-06T21:00:00Z
VOLUME
676907
Market Cap
450.93M

Momentum Score

…

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.71
Low
10.80
High
52 Week Price Range
5.50
Low
24.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
9.36
Dividend Yield
-
Revenue TTM
29.37M
Revenue Per Share
1.05
Gross Profit TTM
-57.41M
Debt / Equity
0.12
ROE
-46.31%
Net Debt
-205.91M
ROCE
-31.93%
Diluted EPS TTM
-3.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -65.78M -80.94M -27.89M 10.64M -203.67M
Net income -65.78M -80.94M -29.73M 9.35M -206.86M
Selling general administrative 46.08M 52.82M 52.87M 46.07M 41.45M
Selling and marketing expenses - - 2.96M - -
Gross profit 64.20M 138.39M 157.75M 205.75M 12.36M
Reconciled depreciation 3.02M 3.54M 2.69M 1.53M 1.19M
Ebit -74.95M -80.94M -27.12M 12.18M -202.85M
Ebitda -71.93M -77.40M -24.16M 11.66M -200.39M
Depreciation and amortization 3.02M 3.54M 2.96M -0.52M 2.46M
Non operating income net other - - - - -0.82M
Operating income -74.95M -95.67M -78.20M 12.18M -202.85M
Other operating expenses 142.18M 234.06M 235.95M 193.58M 215.21M
Interest expense 0.01M 0.00M 0.77M 0.42M 2.67M
Tax provision 0.00M -0.00M 2.87M 1.29M -
Interest income 10.10M 15.20M 12.29M 2.58M 0.75M
Net interest income 10.10M 15.20M 10.73M -0.42M -1.92M
Income tax expense -75.88M -0.00M 1.83M 1.29M 3.19M
Total revenue 67.22M 138.39M 157.75M 205.75M 12.36M
Total operating expenses 139.15M 234.06M 235.95M 193.58M 215.21M
Cost of revenue 3.02M 3.54M 2.96M - -
Total other income expense net 9.17M 14.72M 50.31M -1.53M -0.82M
Net income from continuing ops -65.78M -80.94M 99.33M 9.35M -203.67M
Net income applicable to common shares - - - 9.35M -203.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 271.15M 344.07M 429.40M 450.39M 392.81M
Other current assets 4.97M 64.98M 7.52M 8.69M 5.10M
Total liab 57.16M 103.09M 150.89M 180.07M 164.60M
Total stockholder equity 213.99M 240.98M 278.51M 270.31M 228.21M
Deferred long term liab - - - - 19.93M
Other current liab 19.68M 32.81M 25.06M 30.23M 23.52M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -514.59M -448.81M -367.87M -338.14M -347.49M
Other liab - - - 22.88M 19.93M
Other assets - - - - 2.08M
Cash 230.91M 237.03M 347.00M 391.88M 370.49M
Total current liabilities 36.38M 65.49M 81.99M 126.98M 99.54M
Current deferred revenue 8.25M 21.93M 47.34M 28.65M 43.48M
Net debt -205.91M -208.48M -316.79M -301.01M -302.88M
Short term debt 4.21M 3.55M 4.31M 60.66M 22.47M
Short long term debt - - - 60.66M 22.47M
Short long term debt total 25.00M 28.55M 30.22M 90.87M 67.61M
Other stockholder equity 728.55M 689.76M 646.35M 608.43M 575.67M
Property plant equipment - - - 44.96M 11.26M
Total current assets 241.45M 305.98M 386.59M 403.33M 378.96M
Long term investments - - - 0.00M 0.52M
Net tangible assets - - - - 228.21M
Net receivables 5.56M 3.97M 32.06M 2.76M 3.37M
Long term debt - - - - 40.63M
Inventory - - 0.00M - -
Accounts payable 4.24M 7.19M 5.28M 7.45M 10.06M
Common stock total equity - - - - 0.03M
Retained earnings total equity - - - - -347.49M
Non currrent assets other 1.89M 1.89M 1.89M 2.09M 2.08M
Non current assets total 29.70M 38.09M 42.81M 47.05M 13.85M
Capital lease obligations 25.00M 28.55M 30.22M 34.10M 6.04M
Long term debt total - - - - 40.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.65M -5.83M -7.73M -3.41M
Change to liabilities - - - 0.00M 32.02M
Total cashflows from investing activities -0.23M -0.65M -2.90M -7.73M -3.41M
Net borrowings 0.00M 0.00M -27.36M -5.00M 46.60M
Total cash from financing activities 13.38M 5.42M -24.09M -2.86M 48.02M
Change to operating activities - - - - 0.45M
Net income -65.78M -80.94M -29.73M 9.35M -203.67M
Change in cash -61.12M -54.98M -45.09M 21.41M -90.43M
Begin period cash flow 293.91M 348.89M 393.98M 372.57M 463.00M
End period cash flow 232.79M 293.91M 348.89M 393.98M 372.57M
Total cash from operating activities -74.27M -59.75M -18.10M 31.99M -135.04M
Issuance of capital stock 12.27M 0.68M 0.61M 0.41M 0.52M
Depreciation 3.02M 3.54M 2.96M 1.53M 1.19M
Other cashflows from investing activities -0.23M -0.65M - - -
Change to inventory - - - - 0.45M
Change to account receivables -1.59M 28.09M -29.30M 0.60M -1.24M
Sale purchase of stock - - - - 1.42M
Other cashflows from financing activities 13.38M 4.74M 2.67M 1.73M 47.50M
Change to netincome - - - - 36.20M
Capital expenditures 0.23M 0.65M 2.90M 7.73M 3.41M
Change receivables - - - - -1.24M
Cash flows other operating - - - - 29.95M
Cash and cash equivalents changes - - - - -90.43M
Change in working capital -39.20M -20.81M 7.38M -12.56M 31.23M
Stock based compensation 25.41M 37.99M 34.65M 30.61M 28.91M
Other non cash items 2.28M 0.47M -33.36M 3.06M 8.38M
Free cash flow -74.27M -60.40M -21.00M 24.27M -138.45M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ARCT
Arcturus Therapeutics Holdings Inc		 0.99
10.58%		 10.35 - 2.48 15.35 2.62 15.04 -25.67
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

10285 Science Center Drive, San Diego, CA, United States, 92121

858 900 2660

https://arcturusrx.com

106

Name Title Year Born
Mr. Joseph E. Payne M.Sc. Founder, Pres, CEO & Director 1972
Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, COO & Sec. 1979
Mr. Andrew H. Sassine MBA CFO & Director 1964
Mr. Lance Kurata Chief Legal Officer NA
Dr. Steven George Hughes M.B.A., M.D. Strategic Clinical Advisor & Member of Scientific Advisory Board 1968
Mr. Keith C. Kummerfeld CPA VP of Fin. & Corp. Controller NA
Dr. Dushyant B. Varshney Ph.D. Exec. VP & Chief Technology Officer NA
Mr. Deepankar Roy Sr. Director of Investor Relations NA
Kyle Gutstadt Sr. Analyst of Investor & PR NA
Mr. Kevin T. Skol Sr. VP of Bus. Devel. & Alliance Management NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…